PE20000270A1 - Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol - Google Patents
Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diolInfo
- Publication number
- PE20000270A1 PE20000270A1 PE1999000123A PE00012399A PE20000270A1 PE 20000270 A1 PE20000270 A1 PE 20000270A1 PE 1999000123 A PE1999000123 A PE 1999000123A PE 00012399 A PE00012399 A PE 00012399A PE 20000270 A1 PE20000270 A1 PE 20000270A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- purin
- diol
- derivatives
- ethylamine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
SE REFIERE A DERIVADOS DE 2-(PURIN-9-IL)-TETRAHIDROFURAN-3,4-DIOL DE FORMULA I, R1 Y R2 SON CICLOALQUIL C3-C8, H, R4R5N-ALQUILO C1-C6, GRUPO a, GRUPO b, -(CH2)fSO2NHg(ALQUILO C1-C4)2-g, CICLOALQUILO C3-C8 OPCIONALMENTE SUSTITUIDO POR -(CH2)pR6, ENTRE OTROS; R3 ES METILO, ETILO, -CH=CH2, n-PROPILO, -CH2CH=CH2, (CH2)qHALOGENO, -(CH2)hY(CH2)iH, -COO(CH2)lH, -CON(CH2)mH((CH2)nH), -CO(CH2)oH, -C((CH2)uH)=NO(CH2)vH, ENTRE OTROS; Y ES O, S, N(CH2)jH; a Y b SON 0-4; 3¾a+b¾5; c, d, e SON 0-3; 2¾c+d+e¾3; f ES 2 o 3; g ES 0-2; p ES 0 o 1; q ES 1 o 2; h ES 1 o 2; i ES O A 1; 1¾h+i¾2; j ES 0-1; 1¾h+i+j¾2; l ES 1-2; m Y n SON 0-2; 0¾m+n¾2; o ES 0-2; u Y v SON 0 o 1; 0¾u+v¾1; R4 Y R5 SON H, ALQUILO C1-C6, ARILO, ARILALQUILO C1-C6, NR4R5, ENTRE OTROS; R6 ES OH, NH2, NHCOCH3, HALOGENO; R7 ES H, ALQUILO C1-C6, ALQUIL C1-C6(ARILO), -CO(ALQUILO C1-C6); X ES NR7, O, S, SO, SO2. UN COMPUESTO PREFERIDO ES (2R,3R,4S,5S)-2-(6-(2,2-DIFENIL-ETILAMINO)-2-[2-(1-METIL-1H-IMIDAZOL-4-IL)-ETILAMINO]-PURIN-9-IL)-5-(3-ETIL-[1,2,4]OXADIAZOL-5-IL)-TETRAHIDRO-FURAN-3,4-DIOL, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION, Y A COMPUESTOS INTERMEDIOS. EL COMPUESTO I ES AGONISTA DEL RECEPTOR A2a DE ADENOSINA Y PUEDE SER UTIL PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS, ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA, ASMA
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9803169.3A GB9803169D0 (en) | 1998-02-14 | 1998-02-14 | Chemical compounds |
GBGB9813533.8A GB9813533D0 (en) | 1998-06-23 | 1998-06-23 | Chemical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20000270A1 true PE20000270A1 (es) | 2000-05-20 |
Family
ID=26313119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE1999000123A PE20000270A1 (es) | 1998-02-14 | 1999-02-11 | Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol |
Country Status (32)
Country | Link |
---|---|
US (1) | US6610665B1 (es) |
EP (1) | EP1056759B1 (es) |
JP (1) | JP2002503669A (es) |
KR (1) | KR20010082512A (es) |
AP (1) | AP2000001881A0 (es) |
AR (1) | AR017457A1 (es) |
AT (1) | ATE223429T1 (es) |
AU (1) | AU757156B2 (es) |
BR (1) | BR9907886A (es) |
CA (1) | CA2319009A1 (es) |
CO (1) | CO4990969A1 (es) |
DE (1) | DE69902758T2 (es) |
DK (1) | DK1056759T3 (es) |
EA (1) | EA200000759A1 (es) |
EE (1) | EE200000358A (es) |
ES (1) | ES2183516T3 (es) |
HK (1) | HK1032062A1 (es) |
HR (1) | HRP20000538A2 (es) |
HU (1) | HUP0100702A3 (es) |
IL (1) | IL137402A0 (es) |
IS (1) | IS5576A (es) |
MA (1) | MA27121A1 (es) |
NO (1) | NO20004045L (es) |
NZ (1) | NZ505812A (es) |
PE (1) | PE20000270A1 (es) |
PL (1) | PL342396A1 (es) |
PT (1) | PT1056759E (es) |
SK (1) | SK12002000A3 (es) |
SV (1) | SV1999000016A (es) |
TR (1) | TR200002355T2 (es) |
WO (1) | WO1999041267A1 (es) |
YU (1) | YU50800A (es) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6514949B1 (en) | 1994-07-11 | 2003-02-04 | University Of Virginia Patent Foundation | Method compositions for treating the inflammatory response |
YU44900A (sh) * | 1998-01-31 | 2003-01-31 | Glaxo Group Limited | Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola |
AR017457A1 (es) * | 1998-02-14 | 2001-09-05 | Glaxo Group Ltd | Compuestos derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol, procesos para su preparacion, composiciones que los contienen y su uso en terapia para el tratamiento de enfermedades inflamatorias. |
AU750462B2 (en) | 1998-06-23 | 2002-07-18 | Glaxo Group Limited | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
GB9813565D0 (en) * | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
GB9813554D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
US6232297B1 (en) | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
US7427606B2 (en) | 1999-02-01 | 2008-09-23 | University Of Virginia Patent Foundation | Method to reduce inflammatory response in transplanted tissue |
US7378400B2 (en) | 1999-02-01 | 2008-05-27 | University Of Virginia Patent Foundation | Method to reduce an inflammatory response from arthritis |
GB9930075D0 (en) * | 1999-12-20 | 2000-02-09 | Glaxo Group Ltd | Medicaments |
US7638496B2 (en) | 2000-02-15 | 2009-12-29 | Valeant Pharmaceuticals North America | Nucleoside analogs with carboxamidine modified monocyclic base |
GB0022695D0 (en) | 2000-09-15 | 2000-11-01 | Pfizer Ltd | Purine Derivatives |
GB0115178D0 (en) * | 2001-06-20 | 2001-08-15 | Glaxo Group Ltd | Compounds |
AU2002362443B2 (en) | 2001-10-01 | 2008-05-15 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof |
AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
US6930093B2 (en) * | 2003-07-10 | 2005-08-16 | Valeant Research & Development | Use of ribofuranose derivatives against inflammatory bowel diseases |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
TWI346109B (en) | 2004-04-30 | 2011-08-01 | Otsuka Pharma Co Ltd | 4-amino-5-cyanopyrimidine derivatives |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
AR049384A1 (es) | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | Derivados de purina |
WO2006028618A1 (en) | 2004-08-02 | 2006-03-16 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity |
EP1778712B1 (en) | 2004-08-02 | 2013-01-30 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity |
US7442687B2 (en) | 2004-08-02 | 2008-10-28 | The University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having A2A agonist activity |
GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
AR058104A1 (es) | 2005-10-21 | 2008-01-23 | Novartis Ag | Compuestos organicos |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
AU2007302263A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as P13K lipid kinase inhibitors |
MX2009004715A (es) | 2006-10-30 | 2009-05-20 | Novartis Ag | Compuestos heterociclicos como agentes antiinflamatorios. |
CA2711637A1 (en) | 2008-01-11 | 2009-07-16 | Novartis Ag | Pyrimidines as kinase inhibitors |
PL2391366T3 (pl) | 2009-01-29 | 2013-04-30 | Novartis Ag | Podstawione benzimidazole do leczenia gwiaździaków |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
AU2010283806A1 (en) | 2009-08-12 | 2012-03-01 | Novartis Ag | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
NZ620020A (en) | 2009-08-17 | 2015-06-26 | Intellikine Llc | Heterocyclic compounds and uses thereof |
WO2011020861A1 (en) | 2009-08-20 | 2011-02-24 | Novartis Ag | Heterocyclic oxime compounds |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
JP2014505088A (ja) | 2011-02-10 | 2014-02-27 | ノバルティス アーゲー | C−METチロシンキナーゼ阻害剤としての[1,2,4]トリアゾロ[4,3−b]ピリダジン化合物 |
WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
EA201391230A1 (ru) | 2011-02-25 | 2014-01-30 | АйАрЭм ЭлЭлСи | Соединения и композиции в качестве ингибиторов trk |
KR20140077916A (ko) | 2011-09-15 | 2014-06-24 | 노파르티스 아게 | 티로신 키나제로서의 6-치환된 3-(퀴놀린-6-일티오)-[1,2,4]트리아졸로[4,3-a]피라딘 |
US9174994B2 (en) | 2011-11-23 | 2015-11-03 | Intellikine, Llc | Enhanced treatment regimens using mTor inhibitors |
JP2015512425A (ja) | 2012-04-03 | 2015-04-27 | ノバルティス アーゲー | チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用 |
EP2968340A4 (en) | 2013-03-15 | 2016-08-10 | Intellikine Llc | COMBINING KINASE INHIBITORS AND USES THEREOF |
WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
BR112017001695A2 (pt) | 2014-07-31 | 2017-11-21 | Novartis Ag | terapia de combinação |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9414193D0 (en) * | 1994-07-14 | 1994-08-31 | Glaxo Group Ltd | Compounds |
TW528755B (en) * | 1996-12-24 | 2003-04-21 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
AR017457A1 (es) * | 1998-02-14 | 2001-09-05 | Glaxo Group Ltd | Compuestos derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol, procesos para su preparacion, composiciones que los contienen y su uso en terapia para el tratamiento de enfermedades inflamatorias. |
AU750462B2 (en) * | 1998-06-23 | 2002-07-18 | Glaxo Group Limited | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
-
1999
- 1999-02-11 AR ARP990100570A patent/AR017457A1/es active IP Right Grant
- 1999-02-11 PE PE1999000123A patent/PE20000270A1/es not_active Application Discontinuation
- 1999-02-11 CO CO99008188A patent/CO4990969A1/es unknown
- 1999-02-12 NZ NZ505812A patent/NZ505812A/en unknown
- 1999-02-12 SV SV1999000016A patent/SV1999000016A/es not_active Application Discontinuation
- 1999-02-12 CA CA002319009A patent/CA2319009A1/en not_active Abandoned
- 1999-02-12 KR KR1020007008866A patent/KR20010082512A/ko not_active Application Discontinuation
- 1999-02-12 PL PL99342396A patent/PL342396A1/xx unknown
- 1999-02-12 EP EP99906229A patent/EP1056759B1/en not_active Expired - Lifetime
- 1999-02-12 HU HU0100702A patent/HUP0100702A3/hu unknown
- 1999-02-12 PT PT99906229T patent/PT1056759E/pt unknown
- 1999-02-12 AU AU26235/99A patent/AU757156B2/en not_active Ceased
- 1999-02-12 BR BR9907886-4A patent/BR9907886A/pt not_active IP Right Cessation
- 1999-02-12 EA EA200000759A patent/EA200000759A1/ru unknown
- 1999-02-12 JP JP2000531459A patent/JP2002503669A/ja active Pending
- 1999-02-12 US US09/622,313 patent/US6610665B1/en not_active Expired - Fee Related
- 1999-02-12 DK DK99906229T patent/DK1056759T3/da active
- 1999-02-12 WO PCT/EP1999/000915 patent/WO1999041267A1/en not_active Application Discontinuation
- 1999-02-12 YU YU50800A patent/YU50800A/sh unknown
- 1999-02-12 MA MA25462A patent/MA27121A1/fr unknown
- 1999-02-12 ES ES99906229T patent/ES2183516T3/es not_active Expired - Lifetime
- 1999-02-12 EE EEP200000358A patent/EE200000358A/xx unknown
- 1999-02-12 AP APAP/P/2000/001881A patent/AP2000001881A0/en unknown
- 1999-02-12 AT AT99906229T patent/ATE223429T1/de not_active IP Right Cessation
- 1999-02-12 SK SK1200-2000A patent/SK12002000A3/sk unknown
- 1999-02-12 DE DE69902758T patent/DE69902758T2/de not_active Expired - Fee Related
- 1999-02-12 IL IL13740299A patent/IL137402A0/xx unknown
- 1999-02-12 TR TR2000/02355T patent/TR200002355T2/xx unknown
-
2000
- 2000-07-25 IS IS5576A patent/IS5576A/is unknown
- 2000-08-11 HR HR20000538A patent/HRP20000538A2/hr not_active Application Discontinuation
- 2000-08-11 NO NO20004045A patent/NO20004045L/no unknown
-
2001
- 2001-04-10 HK HK01102563A patent/HK1032062A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20000270A1 (es) | Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol | |
PE20000280A1 (es) | Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol | |
DK1392312T3 (da) | Triazolo-4,5 d-pyrimidinderivater og anvendelse deraf som purinerge receptorantagonister | |
PE20010430A1 (es) | DERIVADOS DE PURINA COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2a | |
PE20020213A1 (es) | DERIVADOS DE PURINA COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2a | |
CN1152042C (zh) | 部分或完全a1激动剂-n6杂环5’硫代腺苷衍生物 | |
RU92016415A (ru) | Нейрозащитные производные индолона и родственные производные | |
CN102504001B (zh) | 3,5-二取代的和3,5,7-三取代的-3H-噁唑并以及3H-噻唑并[4,5-d]嘧啶-2-酮化合物及其前药 | |
PE20010755A1 (es) | DERIVADOS DE PURINA COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2a | |
PE20030256A1 (es) | Nucleosidos 4 sustituidos como inhibidores de la replicacion del arn del virus de la hepatitis c | |
PE20130242A1 (es) | Derivados de isoxazolo-piridina | |
EA200601160A1 (ru) | 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов | |
ATE405270T1 (de) | Pyrrolo 2,3-d pyrimidine und deren verwendung als purinreceptor antagonisten | |
NZ522326A (en) | Adenosine A2A receptor antagonists | |
ATE147074T1 (de) | Verbindungen welche antihypertensive und antiischemische eigenschaften besitzen | |
PE20000013A1 (es) | Derivados de adenosina | |
KR950032263A (ko) | 2'-에테르 그룹을 갖는 뉴클레오사이드 및 올리고 뉴클레오타이드 | |
ATE261982T1 (de) | Salze von di(uridine 5'-tetraphosphate), verfahren zur herstellung und verwendungen davon | |
ATE471323T1 (de) | Purinderivate als antagonisten an purinergen rezeptoren | |
ATE418555T1 (de) | A2a-adenosinrezeptorantagonisten | |
ATE407935T1 (de) | Thieno(3,2-d)pyrimidine und furano(3,2- d)pyrimidine und deren verwendung als antagonisten an purinergen rezeptoren | |
PE20061371A1 (es) | Derivados de 2-metil-4-fenil-5-oxo-1,4,5,6,7,8-hexahidroquinolina | |
CN101212968B (zh) | 3,5-二取代的和3,5,7-三取代的-3H-噁唑并以及3H-噻唑并[4,5-d]嘧啶-2-酮化合物及其前药 | |
DE69935849D1 (de) | Optisch aktive aminopentan-derivate | |
KR930019640A (ko) | 테트라히드로피리미딘 유도체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |